The 2-[7-(2-carboxy-phenyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-benzoic acid (A) forms two polymorphic solvates with pyridine. The polymorphs arise from differences in the hydrogen bond interactions. Two different solvates of A with quinoline are also prepared and structurally characterized. These quinoline solvates are formed via encapsulation of quinoline in the assemblies of quinoline with A. The quinoline molecules in these solvates are hydrogen bonded to dicarboxylic acid (A) through different types of hydrogen bonds. The solvates of 3-[7-(3-carboxy-phenyl)-1,3,6,8-tetraoxo-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-benzoic acid (B) with pyridine or quinoline form assemblies which encapsulate additional pyridine or quinoline molecules.
No takes yet. Share an insight, caveat, or question.
Singh et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: